I understand this I hope Amarin can achieve adequate growth in scripts to capture the EPA market...so far it hasn't happened AMR102 combo was completely shut down, and numerous trials on clinical trials.com are NOT using Vascepa as EPA compound. (This could cause failure of studies in treatments V could have penetrated).
I only see 16 Amarin listed sales positions & have no idea how many are new vs. fill ins. I'm not a fan of Amarin trying to hide increasing sales jobs....they don't update them on their web page.
Market Data 
Markets 
AI
